Sophiris Bio Inc (SPHS) is Reiterated by Maxim Group to Buy, Raises Price Target to $ 6

Sophiris Bio Inc (SPHS) was Reiterated by Maxim Group to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 6 from a previous price target of $4 . Maxim Group advised their investors in a research report released on Aug 10, 2016.

Sophiris Bio Inc closed down -0.22 points or -4.10% at $5.15 with 11,89,221 shares getting traded on Monday. Post opening the session at $5.3, the shares hit an intraday low of $5.1 and an intraday high of $5.37 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Jan 23, 2015, Lars Ekman (director) sold 9,663 shares at $0.47 per share price.

Sophiris Bio Inc. formerly Protox Therapeutics Inc. is a Canada-based biopharmaceutical company focused on the research development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate PRX302 which has completed three clinical trials for the treatment of BPH as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Sophiris Bio Inc

Leave a Reply

Sophiris Bio Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sophiris Bio Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.